Duchenne Muscular Dystrophy

Shot to the heart: J&J punts on Capricor & its cardiac stem cell program

Capricor

How is the stem cell and regenerative medicine biotech sector doing these days and does recent news about specific biotechs such as Capricor suggest issues for the sector more broadly? Capricor had bad news earlier this year related to its stem cells for heart disease program and things just took a turn for the worse …

Shot to the heart: J&J punts on Capricor & its cardiac stem cell program Read More »

Upbeat prospects for some California clinical trial efforts from CIRM

Asterias-cells

Over at the California Stem Cell Report, David Jensen is reporting on some good news from CIRM for California on the stem cell clinical trial front. Stem cell biotechs Asterias and Capricor have stem cell trials supported by 20+ million in CIRM funding each and have been hitting milestones. These trials are progressing and so far have good safety …

Upbeat prospects for some California clinical trial efforts from CIRM Read More »

Internal FDA Fighting on Sarepta Bad Omen for Stem Cell Oversight?

Exondys-51-Sarepta-

The FDA caused major controversy by approving the drug Exondys 51 from Sarepta Therapeutics for treating Duchenne muscular dystrophy over the recommendations of a scientific panel it convened that had voted 7-3 against approval. Is this contentious Sarepta approval serve as a sign of how the FDA will deal with stem cells moving forward? Will the FDA approval, which …

Internal FDA Fighting on Sarepta Bad Omen for Stem Cell Oversight? Read More »